Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

New research suggests that commonly used medications like antibiotics, antivirals, and anti-inflammatories could lower the ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

Findings from a large-scale review indicate certain medications may influence dementia risk, offering insights for prevention ...